Alteon Inc. to Present at The Needham & Company Third Annual Biotechnology Conference
June 08 2004 - 11:30AM
PR Newswire (US)
Alteon Inc. to Present at The Needham & Company Third Annual
Biotechnology Conference - Presentation to be Webcast - PARSIPPANY,
N.J., June 8 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT)
announced today that Kenneth I. Moch, President and Chief Executive
Officer, will present a company update at the Needham & Company
Third Annual Biotechnology Conference at the New York Palace Hotel
on Wednesday, June 16, 2004 at 2:30 p.m., ET. The conference will
be webcast and can be accessed at
http://www.wsw.com/webcast/needham8/alt/. The presentation will be
archived at Alteon's website, http://www.alteon.com/. Note to
Conference Attendees: Alteon has made time available for one-on-one
meetings at the conference. Please contact Susan Pietropaolo at or
201-818-5537 if you are interested in setting up a meeting. About
Alteon Alteon is developing several new classes of drugs that
reverse or slow down diseases of aging and complications of
diabetes. These compounds have an impact on a fundamental
pathological process caused by protein-glucose complexes called
Advanced Glycation End-products (A.G.E.s). The formation and
crosslinking of A.G.E.s lead to a loss of flexibility and function
in body tissues, organs and vessels and have been shown to be a
causative factor in many age-related diseases and diabetic
complications. Alteon has created a library of novel classes of
compounds targeting the A.G.E. Pathway. Alteon's lead compound
alagebrium chloride (formerly ALT-711), the only A.G.E. Crosslink
Breaker in advanced human testing, has demonstrated safety and
efficacy in several Phase 2 trials and is actively being developed
for systolic hypertension and heart failure. Ongoing clinical
trials include SPECTRA (Systolic Pressure Efficacy and Safety Trial
of Alagebrium) and PEDESTAL (Patients with Impaired Ejection
Fraction and Diastolic Dysfunction: Efficacy and Safety Trial of
ALagebrium). For more information on Alteon, visit the company's
website at http://www.alteon.com/. Any statements contained in this
press release that relate to future plans, events or performance
are forward-looking statements that involve risks and uncertainties
including, but not limited to, those relating to technology and
product development (including the possibility that early clinical
trial results may not be predictive of results that will be
obtained in large-scale testing or that any clinical trials will
not demonstrate sufficient safety and efficacy to obtain requisite
approvals or will not result in marketable products), regulatory
approval processes, intellectual property rights and litigation,
competitive products, ability to obtain financing, and other risks
identified in Alteon's filings with the Securities and Exchange
Commission. The information contained in this press release is
accurate as of the date indicated. Actual results, events or
performance may differ materially. Alteon undertakes no obligation
to publicly release the result of any revision to these
forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. DATASOURCE: Alteon Inc. CONTACT: Susan M.
Pietropaolo, Director, Corporate Communications & Investor
Relations, +1-201-818-5537 dir., Web site:
http://www.alteonpharma.com/
Copyright
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Ishares Diversified Alternatives Trust (American Stock Exchange): 0 recent articles
More Alteon , News Articles